Recent News

• 08.06.2026 - Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
• 07.27.2026 - Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
• 06.03.2026 - Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
• 05.28.2026 - Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
• 05.12.2026 - Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
• 05.07.2026 - Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
• 05.04.2026 - Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
• 04.30.2026 - Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
• 04.17.2026 - Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
• 03.24.2026 - Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

Recent Filings

• 08.06.2026 - S-3 Registration statement under Securities Act of 1933
• 08.06.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2026 - 8-K Current report
• 08.06.2026 - EX-99.1 EX-99.1
• 08.06.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 06.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2026 - 4 Statement of changes in beneficial ownership of securities